Liquidia Reports Strong First Quarter Earnings for Q1 2026
Liquidia (LQDA) reported strong financial results for the first quarter of 2026, with significant sequential growth in net product sales and profitability. The company's YUTREPIA drug drove revenue to $129.9 million, up from $90.1 million in Q4 2025, while non-GAAP adjusted EBITDA rose sharply as well.
Tickers: $LQDA